ICG-001
Based on 66 publication(s) in Google Scholar
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 780757-88-2
- Formula: C33H32N4O4
- Molecular Weight:548.63
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ICG-001
More- Signal Transduct Target Ther. 2023 Jan 11;8(1):16. [Abstract]
- Cancer Commun (Lond). 2024 Apr;44(4):469-490. [Abstract]
- Mol Cell. 2025 Sep 18;85(18):3486-3504.e7. [Abstract]
- Cancer Res. 2025 Jan 15;85(2):263-276. [Abstract]
- Cancer Res. 2019 Aug 15;79(16):4160-4172. [Abstract]
- Sci Immunol. 2026 Mar 20;11(117):eadw8291. [Abstract]
- Nat Commun. 2022 Nov 2;13(1):6552. [Abstract]
- Nat Commun. 2022 Jul 28;13(1):4364. [Abstract]
- Acta Pharm Sin B. 2024 Sep;14(9):4118-4133. [Abstract]
- Acta Pharm Sin B. 2022 Mar;12(3):1225-1239. [Abstract]
- J Exp Clin Cancer Res. 2017 Sep 11;36(1):125. [Abstract]
- Nat Cardiovasc Res. 2024 Apr 25:1-7.
- MedComm. 2023 Jun 19;4(4):e301. [Abstract]
- Cancer Lett. 2024 Nov 28:605:217284. [Abstract]
- Int J Biol Sci. 2024 Jun 3;20(8):3185-3200. [Abstract]
- Cell Death Dis. 2025 Dec 13. [Abstract]
- Cell Death Dis. 2018 Jul 18;9(8):793. [Abstract]
- ACS Appl Mater Interfaces. 2025 Feb 12;17(6):8886-8900. [Abstract]
- ACS Appl Mater Interfaces. 2023 Feb 22;15(7):9010-9023. [Abstract]
- Chemosphere. 2024 Jul 3:142758. [Abstract]
- Neoplasia. 2025 Oct 23:70:101242. [Abstract]
- Oncogene. 2026 May;45(16):1411-1424. [Abstract]
- Cell Chem Biol. 2022 Sep 15;29(9):1396-1408.e8. [Abstract]
- Cell Death Discov. 2025 May 17;11(1):241. [Abstract]
- Elife. 2023 Jan 16:12:e81438. [Abstract]
- J Pineal Res. 2019 Sep;67(2):e12588. [Abstract]
- J Agric Food Chem. 2026 Mar 25;74(11):9281-9293. [Abstract]
- JCI Insight. 2023 Jan 24;8(2):e162060. [Abstract]
- Int J Mol Med. 2023 Oct;52(4):91. [Abstract]
- J Ethnopharmacol. 2026 Mar 25:359:121125. [Abstract]
- J Ethnopharmacol. 2023 Oct 28:315:116657. [Abstract]
- Mol Ther Oncolytics. 2019 Mar 29:13:58-66. [Abstract]
- Cells. 2022 Nov 12;11(22):3580. [Abstract]
- Int J Mol Sci. 2022 Jul 28;23(15):8347. [Abstract]
- Int J Mol Sci. 2018 Jul 6;19(7). pii: E1981. [Abstract]
- Cancer Sci. 2016 Dec;107(12):1776-1784. [Abstract]
- J Ovarian Res. 2025 Jul 2;18(1):139. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jan 6:167656. [Abstract]
- FASEB J. 2023 Apr;37(4):e22873. [Abstract]
- J Cell Mol Med. 2023 Mar;27(5):659-671. [Abstract]
- Diabetol Metab Syndr. 2022 Feb 9;14(1):28. [Abstract]
- Sci Rep. 2022 Feb 23;12(1):3053. [Abstract]
- Neurochem Res. 2025 Dec 11;51(1):12. [Abstract]
- J Virol. 2022 Sep 28;96(18):e0096222. [Abstract]
- Cell Signal. 2025 Jun:130:111668. [Abstract]
- Am J Pathol. 2026 Mar 26:S0002-9440(26)00073-8. [Abstract]
- Am J Pathol. 2024 Jun 13:S0002-9440(24)00201-3. [Abstract]
- Food Chem Toxicol. 2024 Jul 23:114888. [Abstract]
- Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F941-F953. [Abstract]
- Am J Physiol Renal Physiol. 2020 Mar 1;318(3):F817-F825. [Abstract]
- J Pharm Biomed Anal. 2022 Sep 20:219:114949. [Abstract]
- Cell Biol Int. 2021 Aug;45(8):1644-1653. [Abstract]
- Exp Biol Med. 2022 Sep;247(17):1548-1557. [Abstract]
- Brain Res. 2026 May 15:1879:150207. [Abstract]
- PLoS One. 2024 Mar 28;19(3):e0298184. [Abstract]
- PLoS One. 2022 Oct 12;17(10):e0274116. [Abstract]
- Biochem Biophys Res Commun. 2026 Feb 19:801:153310. [Abstract]
- bioRxiv. 2026 Jun 9.
- SSRN. 2024 Apr 5.
- SSRN. 2024 Apr 5.
- Research Square Preprint. 2023 Aug 21.
- bioRxiv. 2023 Feb 24.
- bioRxiv. 2023 Feb 10.
- Research Square Preprint. 2021 Apr.
- Small Ruminants Res. 178 (2019) 30-36.
- Oncotarget. 2017 Dec 1;8(70):115089-115101. [Abstract]
-
WB
-
WB
-
WB
-
WB
-
IHC
Biological Activity
IC50: 3 μM (CBP)
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
6.1 μM
Compound: ICG001
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 24950489] |
| A549 | IC50 |
54.1 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-independent human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-independent human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
| CT26 | IC50 |
18.59 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-dependent mouse CT26 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-dependent mouse CT26 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
| HCT-116 | IC50 |
32.71 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-dependent human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-dependent human HCT-116 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
| HCT-116 | IC50 |
38 μM
Compound: ICG-001
|
Antiproliferative activity against beta-catenin signalling overexpressing human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against beta-catenin signalling overexpressing human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 34270257] |
| HCT-116 | IC50 |
38 μM
Compound: ICG-001
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| HEK293 | IC50 |
75.39 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-independent human HEK293 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-independent human HEK293 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
| HepG2 | GI50 |
12.7 μM
Compound: ICG001
|
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 24950489] |
| HT-29 | GI50 |
17.2 μM
Compound: ICG001
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 24950489] |
| HT-29 | IC50 |
10.8 μM
Compound: ICG-001
|
Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
|
[PMID: 34062253] |
| HT-29 | IC50 |
18.7 μM
Compound: ICG001
|
Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
|
[PMID: 24950489] |
| LoVo | GI50 |
15.6 μM
Compound: ICG001
|
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 24950489] |
| MCF-10A | IC50 |
21 μM
Compound: ICG-001
|
Cytotoxicity against human MCF-10A cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 34270257] |
| MCF-10A | IC50 |
21 μM
Compound: ICG-001
|
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| MDA-MB-231 | IC50 |
7.2 μM
Compound: ICG-001
|
Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 34270257] |
| MDA-MB-231 | IC50 |
7.2 μM
Compound: ICG-001
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| MDA-MB-468 | IC50 |
31 μM
Compound: ICG-001
|
Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-468 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-468 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 34270257] |
| MDA-MB-468 | IC50 |
31 μM
Compound: ICG-001
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| RKO | IC50 |
77.48 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-independent human RKO cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-independent human RKO cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
| SW480 | IC50 |
1.3 μM
Compound: ICG-001
|
Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis
Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis
|
[PMID: 23232060] |
| SW480 | IC50 |
6.1 μM
Compound: ICG-001
|
Antiproliferative activity against beta-catenin signalling overexpressing human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against beta-catenin signalling overexpressing human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 34270257] |
| SW480 | IC50 |
6.1 μM
Compound: ICG-001
|
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| SW480 | IC50 |
8.43 μM
Compound: ICG-001
|
Antiproliferative activity against Wnt-dependent human SW480 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against Wnt-dependent human SW480 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK-8 assay
|
[PMID: 36630177] |
ICG-001 (5μM) inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells[1]. ICG-001 can phenotypically rescue normal nerve growth factor (NGF)-induced neuronal differentiation and neurite outgrowth in the presenilin-1 mutant cells, emphasizing the importance of the TCF/β-catenin signaling pathway on neurite outgrowth and neuronal differentiation[2]. ICG-001 (25μM) treatment reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein in SW480 cells, both of which can be up-regulated by β-catenin. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, and reduces in vitro growth of colon carcinoma cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 780757-88-2
-
Appearance Solid
-
Molecular Weight 548.63
-
Formula C33H32N4O4
-
Color Off-white to light yellow
-
SMILES
O=C(NCC1=CC=CC=C1)N2CCC(N([C@@]2(CN(C3=O)CC4=C5C=CC=CC5=CC=C4)[H])[C@H]3CC6=CC=C(C=C6)O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (66)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation. [Abstract]2023 Jan 11;8(1):16. PMID: 36627278 -
Cancer Commun (Lond)
N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer. [Abstract]2024 Apr;44(4):469-490. PMID: 38512764 -
Mol Cell
mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport. [Abstract]2025 Sep 18;85(18):3486-3504.e7. PMID: 40972529 -
Cancer Res
Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis. [Abstract]2025 Jan 15;85(2):263-276. PMID: 39412948 -
Cancer Res
NOTCH Signaling via WNT Regulates the Proliferation of Alternative, CCR2-Independent Tumor-Associated Macrophages in Hepatocellular Carcinoma. [Abstract]2019 Aug 15;79(16):4160-4172. PMID: 31266773 -
Sci Immunol
2026 Mar 20;11(117):eadw8291. PMID: 41860994 -
Nat Commun
Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis. [Abstract]2022 Nov 2;13(1):6552. PMID: 36323713 -
Nat Commun
Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes. [Abstract]2022 Jul 28;13(1):4364. PMID: 35902588 -
Acta Pharm Sin B
Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB interruption. [Abstract]2024 Sep;14(9):4118-4133. PMID: 39309507 -
Acta Pharm Sin B
WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit. [Abstract]2022 Mar;12(3):1225-1239. PMID: 35530152 -
J Exp Clin Cancer Res
ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. [Abstract]2017 Sep 11;36(1):125. PMID: 28893318
ICG-001 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2017 Sep 11;36(1):125. [Abstract]
ICG-001 mediates the association of β-catenin with CBP, P300, E-cadherin and N-cadherin. a and b Western blotting analysis of Wnt related proteins from total proteins and extracted nuclear and cytoplasmic proteins.
-
-
MedComm
Attenuation of amyloid-β-induced mitochondrial dysfunction by active components of anthocyanins in HT22 neuronal cells. [Abstract]2023 Jun 19;4(4):e301. PMID: 37346934 -
Cancer Lett
Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. [Abstract]2024 Nov 28:605:217284. PMID: 39366545 -
Int J Biol Sci
2024 Jun 3;20(8):3185-3200. PMID: 38904026 -
Cell Death Dis
Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors. [Abstract]2025 Dec 13. PMID: 41390817 -
Cell Death Dis
Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. [Abstract]2018 Jul 18;9(8):793. PMID: 30022048
ICG-001 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Jul 18;9(8):793. [Abstract]
BMDMs are cultured with the conditional medium (CM) that is collected from cultured Hepa1-6 cells for 24 h. Meanwhile BMDMs are treated with or without ICG001. The M2-related markers and downstream genes of Wnt signaling are detected by western blotting.
-
ACS Appl Mater Interfaces
Eu-Doped TiO2 Coatings via One-Step In Situ Preparation Enhance Macrophage Polarization and Osseointegration of Implants. [Abstract]2025 Feb 12;17(6):8886-8900. PMID: 39885805 -
ACS Appl Mater Interfaces
Wnt3a-Modified Nanofiber Scaffolds Facilitate Tendon Healing by Driving Macrophage Polarization during Repair. [Abstract]2023 Feb 22;15(7):9010-9023. PMID: 36758166 -
Chemosphere
PFDA promotes cancer metastasis through macrophage M2 polarization mediated by Wnt/β-catenin signaling. [Abstract]2024 Jul 3:142758. PMID: 38969224 -
Neoplasia
Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma. [Abstract]2025 Oct 23:70:101242. PMID: 41135362 -
Oncogene
CAPRIN1-mediated sequestration of NCOA4 mRNA into stress granules drives sorafenib resistance in hepatocellular carcinoma. [Abstract]2026 May;45(16):1411-1424. PMID: 41896589 -
Cell Chem Biol
Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma. [Abstract]2022 Sep 15;29(9):1396-1408.e8. PMID: 35905743 -
Cell Death Discov
Matrix metalloproteinase-10 promotes kidney fibrosis by transactivating β-catenin signaling. [Abstract]2025 May 17;11(1):241. PMID: 40382334 -
Elife
2023 Jan 16:12:e81438. PMID: 36645741 -
J Pineal Res
MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression. [Abstract]2019 Sep;67(2):e12588. PMID: 31140197 -
J Agric Food Chem
Proline Alleviates Low-Protein Diet-Induced Adverse Pregnancy Outcomes by Enriching Akkermansia and Activating Placental Wnt/Igf1 Signaling. [Abstract]2026 Mar 25;74(11):9281-9293. PMID: 41812033 -
JCI Insight
Insulin-like growth factor 2 mRNA-binding protein 3 promotes kidney injury by regulating β-catenin signaling. [Abstract]2023 Jan 24;8(2):e162060. PMID: 36520532 -
Int J Mol Med
Toxoplasma gondii excretory/secretory proteins promotes osteogenic differentiation of bone marrow mesenchymal stem cells via aerobic glycolysis mediated by Wnt/β‑catenin signaling pathway. [Abstract]2023 Oct;52(4):91. PMID: 37594122 -
J Ethnopharmacol
YiQi GuBen formula targets EHMT2 and enhances NEDD4L transcription to combat epithelial-mesenchymal transition and airway remodeling in asthma. [Abstract]2026 Mar 25:359:121125. PMID: 41475628 -
J Ethnopharmacol
Medicinal and edible plant Allium macrostemon Bunge for the treatment of testosterone-induced androgenetic alopecia in mice. [Abstract]2023 Oct 28:315:116657. PMID: 37244409 -
Mol Ther Oncolytics
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. [Abstract]2019 Mar 29:13:58-66. PMID: 31016228 -
Cells
Targeting Wnt/β-Catenin Signaling Exacerbates Ferroptosis and Increases the Efficacy of Melanoma Immunotherapy via the Regulation of MITF. [Abstract]2022 Nov 12;11(22):3580. PMID: 36429010 -
Int J Mol Sci
Functionalized 3D-Printed ST2/Gelatin Methacryloyl/Polcaprolactone Scaffolds for Enhancing Bone Regeneration with Vascularization. [Abstract]2022 Jul 28;23(15):8347. PMID: 35955478 -
Int J Mol Sci
Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer. [Abstract]2018 Jul 6;19(7). pii: E1981. PMID: 29986466
ICG-001 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2018 Jul 6;19(7). pii: E1981. [Abstract]
Cells exposed to ICG-001 for 24 h under different concentrations of (0, 6, 8 μM) are analyzed by Western blot for full-length PARP and cleaved PARP, with β-actin being a loading control.
-
Cancer Sci
Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer. [Abstract]2016 Dec;107(12):1776-1784. PMID: 27709738
ICG-001 purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2016 Dec;107(12):1776-1784. [Abstract]
The amount of ABCC3 protein is increased by ICG-001 treatment in HT-29 cells.
-
J Ovarian Res
TRIB3 regulates Cx43 expression in human granulosa cells via the Wnt/β-catenin signaling pathway: an in vitro study. [Abstract]2025 Jul 2;18(1):139. PMID: 40605006 -
Biochim Biophys Acta Mol Basis Dis
Renal tubular S100A7a impairs fatty acid oxidation and exacerbates renal fibrosis via both intracellular and extracellular pathway. [Abstract]2025 Jan 6:167656. PMID: 39778778 -
FASEB J
Long non-coding RNA SNHG11 regulates the Wnt/β-catenin signaling pathway through rho/ROCK in trabecular meshwork cells. [Abstract]2023 Apr;37(4):e22873. PMID: 36929360 -
J Cell Mol Med
ASPP2 suppresses tumour growth and stemness characteristics in HCC by inhibiting Warburg effect via WNT/β-catenin/HK2 axis. [Abstract]2023 Mar;27(5):659-671. PMID: 36752127 -
Diabetol Metab Syndr
Trigonelline reverses high glucose-induced proliferation, fibrosis of mesangial cells via modulation of Wnt signaling pathway. [Abstract]2022 Feb 9;14(1):28. PMID: 35139912 -
Sci Rep
PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β-catenin signaling pathways. [Abstract]2022 Feb 23;12(1):3053. PMID: 35197539 -
Neurochem Res
PRMT5 Aggravates Parkinson's Disease Progression Through the Inhibition of Neuronal Autophagy Through DKK1. [Abstract]2025 Dec 11;51(1):12. PMID: 41379372 -
J Virol
Transmissible Gastroenteritis Virus Infection Promotes the Self-Renewal of Porcine Intestinal Stem Cells via Wnt/β-Catenin Pathway. [Abstract]2022 Sep 28;96(18):e0096222. PMID: 36073923 -
Cell Signal
GC-MSCs transcriptionally upregulate SALL4 in gastric cancer through miR-4669/TIMP3/β-catenin signaling. [Abstract]2025 Jun:130:111668. PMID: 39965736 -
Am J Pathol
Growth Differentiation Factor 11 Promotes Corneal Endothelial Injury Repair by Activating the SRY-Box Transcription Factor 9-β-Catenin Signaling Pathway. [Abstract]2026 Mar 26:S0002-9440(26)00073-8. PMID: 41903789 -
Am J Pathol
TGFβ1-Induced Fibrotic Responses of Conjunctival Fibroblasts through the Wnt/β-Catenin/CRYAB Signaling Pathway. [Abstract]2024 Jun 13:S0002-9440(24)00201-3. PMID: 38879081 -
Food Chem Toxicol
Polystyrene microplastics facilitate renal fibrosis through accelerating tubular epithelial cell senescence. [Abstract]2024 Jul 23:114888. PMID: 39053876 -
Am J Physiol Renal Physiol
Soluble (pro)renin receptor promotes the fibrotic response in renal proximal tubule epithelial cells in vitro via the Akt/β-catenin/Snail signaling pathway. [Abstract]2020 Nov 1;319(5):F941-F953. PMID: 32865015 -
Am J Physiol Renal Physiol
Soluble (pro)renin receptor regulation of ENaC involved in aldosterone signaling in cultured collecting duct cells. [Abstract]2020 Mar 1;318(3):F817-F825. PMID: 31841392 -
J Pharm Biomed Anal
Quantitative determination of ICG-001 in rat plasma using HPLC-MS/MS: A pharmacokinetic study. [Abstract]2022 Sep 20:219:114949. PMID: 35863168 -
Cell Biol Int
Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition. [Abstract]2021 Aug;45(8):1644-1653. PMID: 33760350 -
Exp Biol Med
The β-catenin/CBP signaling axis participates in sepsis-induced inflammatory lung injury. [Abstract]2022 Sep;247(17):1548-1557. PMID: 35665630 -
Brain Res
Mesenchymal stem cell-derived exosomes rescue stress-dependent morphological deficits in primary hippocampal neurons via Wnt5a/β-catenin/WAVE2 pathway. [Abstract]2026 May 15:1879:150207. PMID: 41698632 -
PLoS One
17β-Estradiol promotes metastasis in triple-negative breast cancer through the Calpain/YAP/β-catenin signaling axis. [Abstract]2024 Mar 28;19(3):e0298184. PMID: 38547301 -
PLoS One
Inhibition of RIP1-RIP3-mediated necroptosis attenuates renal fibrosis via Wnt3α/β-catenin/GSK-3β signaling in unilateral ureteral obstruction. [Abstract]2022 Oct 12;17(10):e0274116. PMID: 36223414 -
Biochem Biophys Res Commun
2026 Feb 19:801:153310. PMID: 41576477 -
-
-
-
-
-
-
-
-
Oncotarget
Insufficient microwave ablation-induced promotion of distant metastasis is suppressed by β-catenin pathway inhibition in breast cancer. [Abstract]2017 Dec 1;8(70):115089-115101. PMID: 29383144
ICG-001 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Dec 1;8(70):115089-115101. [Abstract]
ICG001 depresses the heat-induced over-expression of EMT markers (N-cadherin, Snail), and partially recovers the expression of E-cadherin in heat-treated SUM-1315 and ZR-75-1 cells.
ICG-001 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Dec 1;8(70):115089-115101. [Abstract]
ICG001 normalizes the down expression of E-cadherin and reduces the over-expression of N-cadherin and snail in residual tumor tissue after insufficient microwave ablation (MWA).
Solvent & Solubility
DMSO : ≥ 50 mg/mL (91.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.56 mM); Suspended solution; Need ultrasonic and warming
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 1.67 mg/mL (3.04 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 17% Solutol HS-15 in Saline
Solubility: 1.67 mg/mL (3.04 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
To evaluate effects of ICG-001 on α-SMA and collagen type 1 expression, RLE-6TN cells are treated with TGF-β1 (0.25 ng/mL) in the presence or absence of ICG-001 (5.0 μM). After 24 h, cells are harvested and mRNA isolated for analysis by qPCR. RNA is reverse-transcribed using SuperScript reverse transcriptase. Quantitative PCR is performed with SYBR-Green PCR using Real-Time PCR System HT7900. The amplification protocol is set as follows: 95°C denaturation for 10 min followed by 40 cycles of 15-s denaturation at 95°C, 1 min of annealing/extension, and data collection at 60°C.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Seven-week-old male C57BL/6J-ApcMin/+and WT C57BL/6J mice are treated orally for 9 weeks with ICG-001a (300 mg/kg per day) or vehicle (1% carboxymethylcellulose), once daily, six times per week. MK-231 is administered in drinking water (160 ppm, dissolved in 8 mM Na2PO4 buffer, pH 7.6). At 16 weeks, the polyp number is counted manually by using a dissecting microscope.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yan D, et al, Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem, 2012, 287(11), 8598-8612. [Content Brief]
[2]. Henderson WR Jr, et al, Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA, 2010, 107(32), 14309-14314. [Content Brief]
[3]. Emami KH, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA, 2004, 101(34), 12682-12687. [Content Brief]
[4]. Liu Y, et al. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017 Sep 11;36(1):125. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8227 mL | 9.1136 mL | 18.2272 mL | 45.5681 mL |
| 5 mM | 0.3645 mL | 1.8227 mL | 3.6454 mL | 9.1136 mL | |
| 10 mM | 0.1823 mL | 0.9114 mL | 1.8227 mL | 4.5568 mL | |
| 15 mM | 0.1215 mL | 0.6076 mL | 1.2151 mL | 3.0379 mL | |
| 20 mM | 0.0911 mL | 0.4557 mL | 0.9114 mL | 2.2784 mL | |
| 25 mM | 0.0729 mL | 0.3645 mL | 0.7291 mL | 1.8227 mL | |
| 30 mM | 0.0608 mL | 0.3038 mL | 0.6076 mL | 1.5189 mL | |
| 40 mM | 0.0456 mL | 0.2278 mL | 0.4557 mL | 1.1392 mL | |
| 50 mM | 0.0365 mL | 0.1823 mL | 0.3645 mL | 0.9114 mL | |
| 60 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7595 mL | |
| 80 mM | 0.0228 mL | 0.1139 mL | 0.2278 mL | 0.5696 mL |